Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics has successfully completed a public offering, raising $15.525 million with the help of Canaccord Genuity as the sole bookrunner. The additional funds, garnered from the full exercise of an over-allotment option, will be directed to support clinical trials for CardiolRx, aimed at treating recurrent pericarditis, and other company expenses.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
